Search

Search Results

1. BRAF-Mutated Glioma

   Gliomas with BRAF alterations are increasingly being recognized with the improved molecular evaluation of gliomas and increased use of next...

   Karisa C. Schreck, Jean M. Mulcahy Levy in Brain Tumors

   Chapter 2023
   

2. Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors

   BRAF ^V600E represents a constitutively active onco-kinase and stands as the most prevalent genetic alteration in thyroid cancer. However, the clinical...

   Fang Sui, Guanjie Wang, ... Peng Hou in Cellular and Molecular Life Sciences

   Article Open access 25 May 2024
   

3. BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report

   BRAF mutations are found in 1–5% of non-small-cell lung cancer (NSCLC), with V600 and non-V600 accounting for approximately 50% each. It has been...

   Lan Jiang, Pirong Yang, ... Juan Li in Journal of Cancer Research and Clinical Oncology

   Article Open access 27 March 2024
   

4. RICTOR/mTORC2 downregulation in BRAF^V600E melanoma cells promotes resistance to BRAF/MEK inhibition

   Background

   The main drawback of BRAF/MEK inhibitors (BRAF/MEKi)-based targeted therapy in the management of BRAF-mutated cutaneous metastatic melanoma...

   Luca Ponzone, Valentina Audrito, ... Enzo Calautti in Molecular Cancer

   Article Open access 16 May 2024
   

5. Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer

   Background

   Resistance mechanisms to combination therapy with dabrafenib plus trametinib remain poorly understood in patients with BRAF ^V600E -mutant...

   Laura Mezquita, Marianne Oulhen, ... Françoise Farace in British Journal of Cancer

   Article Open access 04 January 2024
   

6. SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF

   Background

   The gene encoding the E3 ubiquitin ligase substrate-binding adapter Speckle-type BTB/POZ protein ( SPOP ) is frequently mutated in prostate...

   Kai Feng, Qing Shi, ... Chenji Wang in Cell & Bioscience

   Article Open access 30 December 2022
   

7. Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma

   The identification of BRAF V600 mutation in multiple cancers beyond melanoma and the development of combined BRAF and MEK targeting agents have...

   Blessie Elizabeth Nelson, Neha K. Reddy, ... Vivek Subbiah in npj Precision Oncology

   Article Open access 25 May 2023
   

8. BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

   Background

   Ameloblastoma in 66% of the cases harbor a somatic mutation of the “mitogen-activated protein kinase” signaling pathway (BRAF V600E). In...

   Marcel Ebeling, Mario Scheurer, ... Frank Wilde in Medical Oncology

   Article Open access 28 April 2023
   

9. BCL-X_L inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF^V600E colorectal cancer

   Metastatic BRAF ^V600E colorectal cancer (CRC) carries an extremely poor prognosis and is in urgent need of effective new treatments. While the BRAF ^V600E...

   Laura J. Jenkins, Ian Y. Luk, ... John M. Mariadason in Cell Death & Disease

   Article Open access 01 March 2024
   

10. BRAF — a tumour-agnostic drug target with lineage-specific dependencies

    In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib for the...

    Aphrothiti J. Hanrahan, Ziyu Chen, ... David B. Solit in Nature Reviews Clinical Oncology

    Article 26 January 2024
    

11. Combined PD-1, BRAF and MEK inhibition in BRAF^V600E colorectal cancer: a phase 2 trial

    While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAF ^V600E colorectal cancer (CRC), response...

    Jun Tian, Jonathan H. Chen, ... Ryan B. Corcoran in Nature Medicine

    Article Open access 26 January 2023
    

12. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF^V600E colorectal tumors

    BRAF ^V600E mutation confers a poor prognosis in metastatic colorectal cancer (CRC) despite combinatorial targeted therapies based on the latest...

    Ana Ruiz-Saenz, Chloe E. Atreya, ... Jean-Philippe Coppé in Nature Cancer

    Article Open access 09 February 2023
    

13. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma

    There have been many recent advances in melanoma therapy. While 50% of melanomas have a BRAF mutation and are a target for BRAF inhibitors, the...

    Alexandra Haugh, Adil I. Daud in American Journal of Clinical Dermatology

    Article 08 February 2024
    

14. BRAF^V600E-mutant metastatic NSCLC: disease overview and treatment landscape

    In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC,...

    David Planchard, Rachel E. Sanborn, ... Egbert F. Smit in npj Precision Oncology

    Article Open access 16 April 2024
    

15. BRAF

    Daniela Furlan, Nora Sahnane in Endocrine Pathology

    Reference work entry 2022
    

16. An updated literature on BRAF inhibitors (2018–2023)

    BRAF is the most common serine-threonine protein kinase and regulates signal transduction from RAS to MEK inside the cell. The BRAF is a highly...

    Lalmohan Maji, Ghanshyam Teli, ... Gurubasavaraja Swamy Purawarga Matada in Molecular Diversity

    Article 20 July 2023
    

17. Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success

    Purpose of Review

    This report highlights several of the recent therapeutic advancements in the treatment of BRAF -mutant tumors, discusses the most...

    Mike Wang, Ryan J. Sullivan, Meghan J Mooradian in Current Oncology Reports

    Article 08 June 2024

18. A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition

    Background: Prognosis for patients with metastatic melanoma has been improved dramatically with the development of BRAF/MEK directed therapy and...

    Elizabeth I. Buchbinder, Anita Giobbie-Hurder, Patrick A. Ott in Investigational New Drugs

    Article 25 April 2023
    

19. Proteostatic reactivation of the developmental transcription factor TBX3 drives BRAF/MAPK-mediated tumorigenesis

    MAPK pathway-driven tumorigenesis, often induced by BRAF ^V600E , relies on epithelial dedifferentiation. However, how lineage differentiation events...

    Zhenlei Zhang, Yufan Wu, ... Li Zhao in Nature Communications

    Article Open access 15 May 2024
    

20. Oncogenic BRAF noncanonically promotes tumor metastasis by mediating VASP phosphorylation and filopodia formation

    BRAF is frequently mutated in various cancer types and contributes to tumorigenesis and metastasis. As an important switch in RAS signaling pathway,...

    Wenting Pan, Yihao Tian, ... Feng Li in Oncogene

    Article 09 September 2023